PolyPid

About PolyPid

PolyPid (NASDAQ: PYPD) is an Israel-based, clinical-stage biopharmaceutical company established in 2008 by Noam Emanuel. The company is focused on developing and commercializing locally administered therapies designed to enhance surgical outcomes. PolyPid operates as a publicly traded entity, having completed its initial public offering on the Nasdaq in June 2020. As a clinical-stage company, PolyPid is currently unprofitable and does not generate significant revenue, with its business model centered on the research and development of its product pipeline, funded through investments and financing rounds.

The cornerstone of PolyPid's approach is its proprietary PLEX (Polymer-Lipid Encapsulation matriX) drug delivery technology. PLEX is a platform composed of alternating layers of polymers and lipids that create a protected reservoir for a drug. This matrix is designed to be anchored at a surgical site, enabling the controlled and continuous release of medication locally over periods ranging from days to several months. This method of administration allows for high concentrations of a drug at the specific site of action while minimizing systemic exposure and associated side effects. The PLEX platform is versatile and can accommodate various drug types, which can be delivered as a paste, an injectable, or as a coating on a medical device.

PolyPid's lead product candidate is D-PLEX100, which is aimed at preventing surgical site infections (SSIs), a major complication in hospital settings. D-PLEX100 contains the broad-spectrum antibiotic doxycycline encapsulated within the PLEX matrix. Administered during surgery, it provides a high local concentration of the antibiotic for up to 30 days. In June 2025, the company announced positive topline results from its SHIELD II Phase 3 trial for D-PLEX100 in patients undergoing abdominal colorectal surgery. The trial demonstrated a statistically significant 58% reduction in SSIs compared to the standard of care. Following these results, PolyPid is preparing for regulatory submissions to the FDA and European Medicines Agency in early 2026. The company is also developing OncoPLEX for the intra-tumoral treatment of solid tumors, which is currently in the preclinical stage.